期刊文献+

自组装型紫杉醇键合物前药的合成与性能 被引量:1

Synthesis and Properties of Self-assembling Paclitaxel Prodrug
下载PDF
导出
摘要 以p-氨基苯乙酸(APA)和六亚甲基二异氰酸酯(HDI)为连接基团,将短链聚乙二醇单甲醚(mPEG)键合到紫杉醇(PTX)上,获得双亲型PTX前药mPEG-APA-PTX和mPEG-HDI-PTX。考察了这两种前药在自主装、体外药物释放动力学、体外细胞毒性和体内血浆清除速率等方面的表现。结果表明:两前药均能在水中自组装形成稳定的纳米颗粒,载药量高达28%;mPEG-HDI-PTX纳米颗粒在水溶液中非常稳定,细胞毒性很弱,在血液系统中清除很快,而mPEG-APA-PTX纳米颗粒在pH=7.4的环境下可缓慢释放出原药PTX,细胞毒性与临床用紫杉醇针剂Tax-ol相当,体内循环时间较Taxol明显延长;mPEG-APA-PTX是一种可自组装、载药量高、体内循环时间长的新型纳米前药。 Two amphiphilic prodrugs, mPEG-APA-PTX and mPEG-HDI-PTX, were prepared by conju- gating PEG monornethyl ether (mPEG) short chains to paclitaxel(PTX) via p-aminophenylacetic (APA) or hexamethylene diisocyanate (HDI) as linkers. The capability of self-assembling, the PTX release kinetics, the cytotoxicity and the life-time in plasma of them were characterized. Results showed that the prodrugs self-assembled into stable nanoparticles in aqueous solution with high drug loading content (280//00). MPEG-HDI-PTX nanoparticles stayed stable in aqueous solution, but completely lost their cytotoxicity and were eliminated rapidly in plasma. While mPEG APA PTX nanoparticles released PTX slowly when pH = 7.4, their cytotoxicity was similar to Taxol and the nanoparticles had a remarkable longer blood cir- culation time than Taxol. In summary, the mPEG-APA-PTX was capable of self-assembly into high drug-loaded and long plasma circulating polymeric nanoparticles.
出处 《功能高分子学报》 CAS CSCD 北大核心 2013年第2期115-122,共8页 Journal of Functional Polymers
关键词 紫杉醇 聚乙二醇 前药 自组装 高载药率 paclitaxel PEG prodrug self assemble high drug-loaded
  • 相关文献

参考文献22

  • 1Wani M C, Taylor H L, Wall M E, etal. Plant antitumor agents: VI. Isolation and structure of taxol, a novel antileuke- mic and antitumor agent from taxus brevifolia[J]. Journal of the American Chemical Society, 1971, 93(9): 2325-2327.
  • 2Suffness M. Taxol: From discovery to therapeutic use[J]. Annual Reports in Medicinal Chemistry, 1993, 28:305-314.
  • 3Singh S, Dash A K. Paclitaxel in cancer treatment: Perspectives and prospects of its delivery challenges[J]. Critical ReviewsTM in Therapeutic Drug Carrier Systems, 2009, 26(4):333-372.
  • 4Marupudi N I, Hart J E, Li K W, et al. Paclitaxel: A review of adverse toxieities and novel delivery strategies[J]. Expert Opinion on Drug Safety, 2007, 6(5) :609-621.
  • 5Sparreboom A, Scripture C D, Trieu V, et al. Comparative preelinicaI and clinical pharmacokinetics of a cremophor-free,nanoparticle albumin bound ,oaclitaxel ( ABI 007) and paelitaxcl formulated in eremophor (Taxol)[J]. Clinical Ca,leer Research, 2005, 11(11) :4136-4143.
  • 6Scripture C D, Flag W D Sparreboom A. Paclitaxel chemotherapy: From empiricism to a mechanism-based formulation strategy[J]. Journal of Therapeutics and Clinical Risk Management, 2005, 1(2): 107 114.
  • 7Zhang Zhingping, Mei I.in, Feng Sishen. Paclitaxel drug delivery systems[J]. Expert Opinion on Drug Delievery, 201::, 10(3):325 340.
  • 8Gradishar W J, Tjulandin S, Davidson N, el al. Superior efficacy of albumin bound paclitaxel, ABI-007, compared with polyethylated castor oil-based paclitaxel in women with metastatic breast cancer= Results of a phase Ill lrial[J] Journal of Clinical Oncology, 2005, 23(31):779/1 7803.
  • 9杨爱珍,李军,徐海军,陈惠英.紫杉醇脂质体的体内外抗肿瘤作用研究[J].中国肿瘤,2006,15(12):862-864. 被引量:17
  • 10乱陈强,张其忠,刘健,等.紫杉醇脂质体与传统紫杉醇治疗乳腺癌和非小细胞肺癌的随机对照研究[J].中华肿瘤条志.2003,25(2):190l92.

二级参考文献6

共引文献16

同被引文献1

引证文献1

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部